Penserra Capital Management LLC Buys Shares of 18,090 TransMedics Group, Inc. $TMDX

Penserra Capital Management LLC purchased a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 18,090 shares of the company’s stock, valued at approximately $2,424,000.

Other large investors have also made changes to their positions in the company. Teacher Retirement System of Texas acquired a new stake in shares of TransMedics Group in the 1st quarter worth $330,000. Principal Financial Group Inc. increased its position in TransMedics Group by 2.8% during the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company’s stock valued at $13,350,000 after buying an additional 5,480 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in TransMedics Group by 1.6% in the first quarter. Nisa Investment Advisors LLC now owns 15,824 shares of the company’s stock valued at $1,065,000 after buying an additional 256 shares during the last quarter. Emerald Advisers LLC boosted its holdings in TransMedics Group by 22.4% in the first quarter. Emerald Advisers LLC now owns 454,794 shares of the company’s stock worth $30,599,000 after acquiring an additional 83,083 shares in the last quarter. Finally, CWM LLC grew its stake in shares of TransMedics Group by 20.1% during the first quarter. CWM LLC now owns 925 shares of the company’s stock worth $62,000 after acquiring an additional 155 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on TMDX. Stifel Nicolaus began coverage on shares of TransMedics Group in a report on Thursday, September 4th. They set a “hold” rating and a $115.00 price objective on the stock. Evercore ISI assumed coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 target price on the stock. Zacks Research cut shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Finally, Jefferies Financial Group started coverage on shares of TransMedics Group in a research note on Monday, October 13th. They set a “buy” rating and a $145.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $130.73.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 4,142 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the completion of the transaction, the director directly owned 2,866 shares in the company, valued at $373,869.70. The trade was a 59.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $119.17 on Monday. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $145.50. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. The company has a market cap of $4.07 billion, a PE ratio of 48.25 and a beta of 2.05. The company’s 50 day moving average is $117.77 and its 200 day moving average is $119.05.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.37 by $0.29. The business had revenue of $143.82 million during the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.12 EPS. TransMedics Group has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.